文献速递浆细胞疾病

通过量化循环克隆浆细胞增强新诊断多发性骨髓瘤的R-ISS分期

Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells.
PubMed 文献 · Am J Hematol · 2020-01-08

本研究在梅奥诊所556例连续新诊断多发性骨髓瘤患者中,评估通过多参数流式细胞术量化循环克隆浆细胞(cPCs)能否为现行R-ISS分期增加预后价值。将cPCs≥5个/μL且R-ISS I或II期患者重新归类为R-ISS IIB期,发现其生存结局差于预期,且cPCs≥5个/μL在多变量模型中保持不良预后意义。

要点

  • cPCs≥5个/μL的R-ISS I或II期患者可重新归类为R-ISS IIB期。
  • R-ISS IIB期中位至下次治疗21个月,总生存45个月。
  • cPCs≥5个/μL在多变量模型中保持不良预后意义。

核心结论

  • 通过多参数流式细胞术量化cPCs可识别R-ISS I和II期中生存差于预期的患者,可能增强R-ISS分期。

研究设计与样本

  • 回顾性分析2009至2017年梅奥诊所罗切斯特院区556例连续新诊断多发性骨髓瘤患者。

主要发现

  • cPCs≥5个/μL且R-ISS I期(N=110)中位至下次治疗40个月,总生存未达到。
  • cPCs≥5个/μL且R-ISS II期(N=69)中位至下次治疗30个月,总生存72个月。
  • cPCs≥5个/μL且R-ISS IIB期(N=96)中位至下次治疗21个月,总生存45个月。
  • cPCs≥5个/μL且R-ISS III期(N=281)中位至下次治疗20个月,总生存47个月。
  • cPCs≥5个/μL在多变量模型中保持对至下次治疗和总生存的不良预后意义。

关键数值与推荐

  • cPCs≥5个/μL且R-ISS I或II期患者重新归类为R-ISS IIB期。

临床怎么用

  • 可考虑通过多参数流式细胞术量化cPCs,识别R-ISS I和II期中预后较差的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our prior studies identified the prognostic significance of quantifying cPCs by multiparametric flow cytometry (MFC) in newly diagnosed multiple myeloma (NDMM) patients. We evaluated if a similar quantification of cPCs could add prognostic value to the current R-ISS classification of 556 consecutive NDMM patients seen at the Mayo Clinic, Rochester from 2009 to 2017. Those patients that had ≥5 cPCs/μL and either R-ISS stage I or stage II disease were re-classified as R-ISS IIB stage for the purposes of this study. The median time to next therapy (TTNT) and overall survival (OS) for patients with ≥5 cPCs/μL at diagnosis was as follows: R-ISS I (N = 110) - 40 months and not reached; R-ISS II (N = 69) - 30 and 72 months; R-ISS IIB (N = 96) - 21 and 45 months and R-ISS III (N = 281) - 20 and 47 months respectively. Finally, ≥ 5 cPCs/μL retained its adverse prognostic significance in a multivariable model for TTNT and OS. Hence, quantifying cPCs by MFC can potentially enhance the R-ISS classification of a subset of NDMM patients with stage I and II disease by identifying those patients with a worse than expected survival outcome.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Gonsalves WI, Jevremovic D, Nandakumar B, et al. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Am J Hematol. 2020. PMID: 31867775. doi:10.1002/ajh.25709

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。